Fig. 4.

Antiviral screening assay for top hits procured from HerpDock:. (A) MTT assay of the drug Rilapladib performed on HCE cells (B) Fluorescence intensity was measured using a plate reader where cells were pre-treated for 24 h with Rilapladib followed by 24 h infection (C) Fluorescence intensity was measured using a plate reader where cells were infected, and drug was administered 2 hpi and cells were collected 24 hpi (D) MTT assay of the drug Bizelesin performed on HCE cells (E) Fluorescence intensity was measured using a plate reader where cells were pre-treated for 24 h with Bizelesin followed by 24 h infection (F) Fluorescence intensity was measured using a plate reader where cells were infected, and drug was administered 2 hpi and cells were collected 24 hpi (G) Beta galactosidase assay of the drug Rilapladip performed on HCE cells that were pre-incubated with the drug for 24 h (H) Western blot assay showing viral entry at different concentrations of Rilapladib performed on pre-treated HCE cells (I) Densitmetric quantification of western blot shown in image H (J) Immunofluroscence images showing viral entry of Rilapladib performed on pre-treated HCE cells compared to DMSO treated (control) (K) Quantification of the images shown in figure J.